Why the study?
Does escalating doses of aspirin improve the inhibition of platelet aggregation in patients at risk for or experiencing stroke?
Population
146 patients, comprising 113 taking aspirin for stroke prevention and 33 with acute stroke taking aspirin…
Design
Cohort
Authors
Loading...
Escalation may restore full inhibition in most but not all; leaves open whether this improves stroke outcomes or warrants resistance testing.
Does escalating doses of aspirin improve the inhibition of platelet aggregation in patients at risk for or experiencing stroke?
The ability of aspirin to inhibit platelet aggregation varies by individual, and some patients exhibit aspirin resistance even at high doses (1,300 mg).
Helgason et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: